Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 366
- Market Cap
- $6.1B
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
SentiSense also tracks daily options readings for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.